Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it is preparing an expanded access FDA protocolto study potential benefit of nebulized treatment with Ampion in SARS-Cov-2... Read More

Wednesday March 25, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio Pharmaceuticals appoints Dan Stokely CFO

Ampio Pharmaceuticals appoints Dan Stokely CFO

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common... Read More

Thursday July 11, 2019 0 comments Tags: Englewood, Ampio Pharmaceuticals, Dan Stokely, Michael Macaluso

Ampio Pharmaceuticals offers $12M in stock to public to fund clinical trial

Ampio Pharmaceuticals offers $12M in stock to public to fund clinical trial

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it will offer up to $12 million of its common stock in a public offering. Ampio said it has entered into agreements... Read More

Tuesday June 18, 2019 0 comments Tags: Englewood, Ampio Pharmaceuticals

Ampio updates regulatory status for Ampion drug

Ampio updates regulatory status for Ampion drug

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it met with the FDA on Dec. 12 to discuss final guidance to achieve regulatory approval for its osteoarthritis drug Ampion.... Read More

Friday December 14, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio provides update on Ampion regulatory review

Ampio provides update on Ampion regulatory review

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reports favorable regulatory and peer-review on the status of Ampion, the companys drug for osteoarthritis of the knee. ... Read More

Tuesday November 27, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio updates Ampion regulatory progress

Ampio updates Ampion regulatory progress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion... Read More

Monday November 12, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso

Ampio Pharmaceuticals announces stock offering to raise $8M

Ampio Pharmaceuticals announces stock offering to raise $8M

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the pricing of an underwritten public offering of 20 million shares of its common stock and warrants to purchase up to... Read More

Monday August 13, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals